NEW YORK, NY, December 11, 2023 – The FDA has cleared an Investigational New Drug Application (IND) for MyMD Pharmaceuticals (Nasdaq: MYMD) to initiate a  Phase 2 clinical trial of oral MYMD-1® as a treatment for rheumatoid arthritis (RA). The company plans to launch the trial in the first quarter of 2024. Chris Chapman, M.D., president, director, and chief … Continue reading MyMD Tackles Rheumatoid Arthritis with Launch of Phase 2 Trial in Early 2024